Tang Capital Management
Latest statistics and disclosures from Tang Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AUPH, GLPG, PTCT, CELC, MIRM, and represent 30.89% of Tang Capital Management's stock portfolio.
- Added to shares of these 10 stocks: RNA (+$65M), CAPR (+$49M), SPY (+$21M), BNTX (+$19M), ANIP (+$13M), MRNA (+$11M), IMCR (+$11M), BMY (+$11M), WVE (+$10M), CORT (+$5.5M).
- Started 9 new stock positions in ACET, CAPR, ABEO, STRO, WVE, BMY, RNA, SPY, CORT.
- Reduced shares in these 10 stocks: TARS (-$104M), MRUS (-$57M), SYRE (-$43M), RLAY (-$42M), VERA (-$39M), NKE (-$36M), IONS (-$36M), CTMX (-$35M), VRDN (-$33M), ACAD (-$32M).
- Sold out of its positions in ADMA, ATYR, ABCL, IVVD, Adicet Bio, BABA, ALL, ALMS, AMZN, AAT.
- Tang Capital Management was a net seller of stock by $-1.0B.
- Tang Capital Management has $2.0B in assets under management (AUM), dropping by -22.08%.
- Central Index Key (CIK): 0001232621
Tip: Access up to 7 years of quarterly data
Positions held by Tang Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tang Capital Management
Tang Capital Management holds 75 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals (AUPH) | 8.9 | $181M | 11M | 15.95 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 6.3 | $128M | -5% | 3.9M | 32.70 |
|
| Ptc Therapeutics I (PTCT) | 5.6 | $114M | 1.5M | 75.96 |
|
|
| Celcuity (CELC) | 5.2 | $105M | -8% | 1.1M | 99.74 |
|
| Mirum Pharmaceuticals (MIRM) | 4.8 | $98M | 1.2M | 78.99 |
|
|
| Tarsus Pharmaceuticals (TARS) | 4.8 | $97M | -51% | 1.2M | 81.88 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 4.6 | $93M | -2% | 2.3M | 41.25 |
|
| Immunocore Hldgs Ads (IMCR) | 4.5 | $91M | +14% | 2.6M | 34.71 |
|
| Compass Therapeutics (CMPX) | 4.5 | $90M | 17M | 5.37 |
|
|
| Kalvista Pharmaceuticals (KALV) | 3.6 | $74M | -9% | 4.6M | 16.15 |
|
| Avidity Biosciences Ord (RNA) | 3.2 | $65M | NEW | 900k | 72.13 |
|
| Anaptysbio Inc Common (ANAB) | 3.2 | $65M | 1.3M | 48.48 |
|
|
| Spyre Therapeutics Com New (SYRE) | 3.1 | $62M | -40% | 1.9M | 32.76 |
|
| Miragen Therapeutics (VRDN) | 2.8 | $56M | -36% | 1.8M | 31.12 |
|
| Capricor Therapeutics Com New (CAPR) | 2.4 | $49M | NEW | 1.7M | 28.86 |
|
| Biontech Se Sponsored Ads (BNTX) | 2.2 | $45M | +74% | 470k | 95.20 |
|
| Biosante Pharmaceuticals (ANIP) | 1.9 | $38M | +51% | 481k | 78.94 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.8 | $36M | 80k | 453.36 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 1.7 | $35M | -8% | 3.9M | 8.96 |
|
| Travere Therapeutics (TVTX) | 1.3 | $27M | 700k | 38.21 |
|
|
| Ventyx Biosciences (VTYX) | 1.3 | $25M | -9% | 2.8M | 9.03 |
|
| NVIDIA Corporation (NVDA) | 1.2 | $24M | -2% | 128k | 186.50 |
|
| Precigen (PGEN) | 1.2 | $24M | -54% | 5.6M | 4.18 |
|
| Spdr S&p 500 Etf Tr Tr Unit (SPY) | 1.0 | $21M | NEW | 30k | 681.92 |
|
| Moderna (MRNA) | 1.0 | $20M | +126% | 693k | 29.49 |
|
| Viking Therapeutics (VKTX) | 0.9 | $18M | -42% | 500k | 35.18 |
|
| Atea Pharmaceuticals (AVIR) | 0.8 | $17M | 4.8M | 3.57 |
|
|
| Stoke Therapeutics (STOK) | 0.8 | $16M | 500k | 31.74 |
|
|
| Ideaya Biosciences (IDYA) | 0.8 | $16M | +12% | 450k | 34.57 |
|
| Meta Platforms Cl A (META) | 0.8 | $15M | -10% | 23k | 660.09 |
|
| GSK Sponsored Adr (GSK) | 0.7 | $15M | -25% | 300k | 49.04 |
|
| Journey Med Corp (DERM) | 0.7 | $14M | 1.9M | 7.71 |
|
|
| Lenz Therapeutics (LENZ) | 0.7 | $14M | -3% | 865k | 16.00 |
|
| Vaxcyte (PCVX) | 0.6 | $13M | -8% | 275k | 46.14 |
|
| Dianthus Therapeutics (DNTH) | 0.5 | $11M | 265k | 41.21 |
|
|
| Harmony Biosciences Hldgs In (HRMY) | 0.5 | $11M | +3% | 290k | 37.42 |
|
| Bristol Myers Squibb (BMY) | 0.5 | $11M | NEW | 200k | 53.94 |
|
| Insmed Com Par $.01 (INSM) | 0.5 | $10M | -70% | 60k | 174.04 |
|
| Crescent Biopharma (CBIO) | 0.5 | $10M | +28% | 872k | 11.86 |
|
| Wave Life Sciences SHS (WVE) | 0.5 | $10M | NEW | 600k | 17.00 |
|
| Teladoc (TDOC) | 0.5 | $9.8M | 1.4M | 7.00 |
|
|
| Dynavax Technologies Corp Com New (DVAX) | 0.4 | $8.6M | -71% | 556k | 15.38 |
|
| Evolus (EOLS) | 0.4 | $8.3M | -77% | 1.2M | 6.65 |
|
| Verastem Com New (VSTM) | 0.4 | $8.3M | +35% | 1.1M | 7.72 |
|
| Urogen Pharma (URGN) | 0.4 | $8.2M | -65% | 350k | 23.42 |
|
| Heron Therapeutics (HRTX) | 0.4 | $8.1M | +81% | 6.3M | 1.30 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $8.0M | -80% | 300k | 26.71 |
|
| Altimmune Com New (ALT) | 0.4 | $7.7M | 2.1M | 3.61 |
|
|
| Sarepta Therapeutics (SRPT) | 0.4 | $7.5M | -41% | 349k | 21.52 |
|
| Pliant Therapeutics (PLRX) | 0.4 | $7.5M | +2% | 6.1M | 1.22 |
|
| Arvinas Ord (ARVN) | 0.3 | $6.8M | -59% | 570k | 11.86 |
|
| Theravance Biopharma (TBPH) | 0.3 | $6.6M | +32% | 351k | 18.71 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.3 | $6.2M | 800k | 7.80 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.3 | $6.2M | +3% | 4.9M | 1.25 |
|
| Regeneron Pharmaceuticals (REGN) | 0.3 | $6.2M | -20% | 8.0k | 771.87 |
|
| Biogen Idec (BIIB) | 0.3 | $6.2M | 35k | 175.99 |
|
|
| Corcept Therapeutics Incorporated (CORT) | 0.3 | $5.5M | NEW | 157k | 34.80 |
|
| Abeona Therapeutics Com New (ABEO) | 0.3 | $5.3M | NEW | 1.0M | 5.27 |
|
| Immunitybio (IBRX) | 0.2 | $4.6M | 2.3M | 1.98 |
|
|
| Kezar Life Sciences Com New (KZR) | 0.2 | $4.2M | -7% | 664k | 6.29 |
|
| Coherus Biosciences (CHRS) | 0.2 | $3.9M | -46% | 2.7M | 1.42 |
|
| Erasca (ERAS) | 0.2 | $3.3M | -40% | 900k | 3.72 |
|
| Nkarta (NKTX) | 0.1 | $2.7M | -79% | 1.5M | 1.85 |
|
| Nuvalent Inc-a (NUVL) | 0.1 | $2.2M | -56% | 22k | 100.59 |
|
| Alexandria Real Estate Equities (ARE) | 0.1 | $2.0M | 40k | 48.94 |
|
|
| Neumora Therapeutics (NMRA) | 0.1 | $1.7M | -30% | 967k | 1.79 |
|
| Sutro Biopharma Com Shs (STRO) | 0.1 | $1.6M | NEW | 140k | 11.57 |
|
| Biohaven (BHVN) | 0.1 | $1.6M | 140k | 11.29 |
|
|
| Revolution Medicines (RVMD) | 0.1 | $1.2M | -84% | 16k | 79.65 |
|
| Fate Therapeutics (FATE) | 0.1 | $1.1M | -37% | 1.2M | 0.98 |
|
| Zymeworks Del (ZYME) | 0.0 | $912k | -96% | 35k | 26.33 |
|
| Rocket Pharmaceuticals (RCKT) | 0.0 | $351k | -88% | 100k | 3.51 |
|
| Adicet Bio Com New (ACET) | 0.0 | $52k | NEW | 6.2k | 8.42 |
|
| Tscan Therapeutics (TCRX) | 0.0 | $46k | -92% | 46k | 1.00 |
|
| Cassava Sciences (SAVA) | 0.0 | $14k | 7.1k | 1.98 |
|
Past Filings by Tang Capital Management
SEC 13F filings are viewable for Tang Capital Management going back to 2011
- Tang Capital Management 2025 Q4 filed Feb. 17, 2026
- Tang Capital Management 2025 Q3 filed Nov. 14, 2025
- Tang Capital Management 2025 Q2 filed Aug. 14, 2025
- Tang Capital Management 2025 Q1 filed May 15, 2025
- Tang Capital Management 2024 Q4 filed Feb. 14, 2025
- Tang Capital Management 2024 Q3 filed Nov. 14, 2024
- Tang Capital Management 2024 Q2 filed Aug. 14, 2024
- Tang Capital Management 2024 Q1 filed May 15, 2024
- Tang Capital Management 2023 Q4 filed Feb. 14, 2024
- Tang Capital Management 2023 Q3 filed Nov. 14, 2023
- Tang Capital Management 2023 Q2 filed Aug. 14, 2023
- Tang Capital Management 2023 Q1 filed May 15, 2023
- Tang Capital Management 2022 Q4 filed Feb. 14, 2023
- Tang Capital Management 2022 Q3 filed Nov. 14, 2022
- Tang Capital Management 2022 Q2 filed Aug. 15, 2022
- Tang Capital Management 2022 Q1 filed May 16, 2022